Digital Contract

@csrf

Back

Survey on Prescribing Patterns and Perceptions of Antiglaucoma Medications and Combinations in Primary Open Angle Glaucoma (POAG)

{{--

Survey Questionnaire Form

--}}

Doctor's details

General Questions

How many patients with Primary Open Angle Glaucoma do you see per month? *

0-10

11-20

21-30

31+

As per your clinical practice, which is the most common age group in patients diagnosed with glaucoma? *

<40 years

40-60 years

61-80 years

> 80 years

What percentage of your POAG patients are Male vs. Female? *

How often do you measure intraocular pressure (IOP) in your POAG patients? *

At every visit

Every 3 months

Every 6 months

Annually

Other

What factors influence your choice of first-line medication? *

Efficacy

Side effects

Cost

Patient preference

Other

Which first-line antiglaucoma medication do you most frequently prescribe? *

Latanoprost

Timolol

Brimonidine

Brinzolamide

Other

What is the average reduction in IOP you observe with first-line medications? *

Which of the following statements about the BAK-free micellar formulation of latanoprost 0.005% ophthalmic solution (e.g., Latoprost RT microemulsion, Sun Pharma, India) are true or false? *

	True	False
It is stabilized by benzalkonium chloride (BAK).
It must be stored at a temperature of 2^º-8^ºC.
It is stable at 40°C for 6 months.
It is prepared using latanoprost, castor oil 0.15%, polyethylene glycol hydroxystearate (Solutol HS), and propylene glycol.
It increases patient compliance due to extended stability at 40^°C.
It causes more corneal toxicity and eye irritation compared to formulations containing BAK.
It does not require BAK for solubilizing latanoprost.
It is increases TBUT, reduces OSDI index when patients are shifted from BAK containing formulation to Latoprost RT

How often do you prescribe combination therapies for POAG? *

Rarely

Sometimes

Often

Always

What factors influence your choice of combination therapy?*

Patient adherence

Efficacy

Side effects

Cost

Other

Which combination therapies do you most commonly prescribe?*

Latanoprost/Timolol

Brimonidine/Brinzolamide

Other

What is the average reduction in IOP you observe with combination therapies? *

Do you believe that brimonidine 0.1% is comparable to brimonidine 0.2% in reducing intraocular pressure (IOP) in Primary Open Angle Glaucoma (POAG) patients? *

Yes, they are comparable in IOP reduction.

No, brimonidine 0.2% is more effective in IOP reduction.

No, brimonidine 0.1% is more effective in IOP reduction.

Unsure / No opinion

Do you believe that brinzolamide has comparable efficacy but better tolerability compared to dorzolamide in the treatment of Primary Open Angle Glaucoma (POAG)? *

Yes, brinzolamide has comparable efficacy and better tolerability.

Yes, brinzolamide has comparable efficacy but similar tolerability.

No, dorzolamide has better efficacy and tolerability.

No, dorzolamide has better efficacy but similar tolerability.

Unsure / No opinion

Are you aware that SYNCA LS is a fixed-dose combination (FDC) of Brimonidine 0.1% and Brinzolamide 1%, and is a BAK-free formulation? [Multiple choice] *

Yes, I am aware

No, I am not aware

Unsure / No opinion

What strategies do you use to improve patient adherence to antiglaucoma medications? *

How do you monitor patient adherence to their medication regimen? *

How often do you switch patients from one antiglaucoma medication to another? [Multiple choice] *

Rarely

Sometimes

Often

Always

What are the common reasons for switching medications? [Multiple choice]*

Lack of efficacy

Side effects

Cost

Patient preference

Other

Are you aware of any new antiglaucoma medications or treatments on the market? *

Yes

How likely are you to adopt new treatments for POAG in your practice? *

Very likely

Somewhat likely

Neutral

Somewhat unlikely

Very unlikely

What challenges do you face in managing POAG in your patients? *

Any additional comments or suggestions regarding the management of POAG? *